Bayer submits vericiguat for marketing authorization in the EU and Japan for the treatment of chronic heart failure (for specialized target groups only)

Regulatory submissions based on positive data from Phase III VICTORIA study recently published in the New England Journal of Medicine (1)
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news